Video

Dr. Slovin on the Future of Immunotherapy in Prostate Cancer

Author(s):

Susan F. Slovin, MD, PhD

In Partnership With:

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

There have been tremendous strides looking at different immune-based platforms, states Slovin. An approach being evaluated is the PROSTVAC platform, which is a transgene of PSA in a fowlpox vector given with 3 immune stimulatory molecules.

There are a variety of molecules to which immunotherapies are being developed including VISTA, LAG-3, FoxP3, explains Slovin.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Gustavo Werutsky, MD, PhD, medical oncologist, Breast Cancer Program, Hospital Moinhos de Vento; investigator, Oncology Research Centre, Hospital São Lucas PUCRS University
Ewa Kalinka, MD, PhD
Rohan Garje, MD
Aparna Parikh, MD, medical oncologist, Massachusetts General Hospital
Tycel J. Phillips, MD, MPH
Dr Baljevic on Selinexor Plus Pomalidomide/Dexamethasone in R/R Myeloma
Dr Al Malki on the Potential Use of TSC-100 and TSC-101 After Transplant in AML, ALL, and MDS
Naval G. Daver, MD,
Ami Umesh Badami, MD, medical oncologist, Endeavor Health Medical Group
Phillip Phillip, MD
Related Content
Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

NGS-Based xT CDx Available in the United States | © Siarhei- stock.adobe.com.
January 15th 2025

NGS-Based xT CDx Test Is Now Commercially Available in United States for Solid Tumor Profiling

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

Roxana S. Dronca, MD
January 13th 2025

FDA Approval of Subcutaneous Nivolumab Represents Paradigm Shift in Solid Tumor Management

Leuprolide Mesylate in Advanced Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
January 13th 2025

PDUFA Date Set for 3-Month Variation of Leuprolide Mesylate in Advanced Prostate Cancer